Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Brittle asthma.

E Graziani1, A Petroianni, C Terzano

  • 1University La Sapienza - Rome (Italy).

European Review for Medical and Pharmacological Sciences
|January 8, 2005
PubMed
Summary
This summary is machine-generated.

Brittle asthma, a severe respiratory condition, presents with unpredictable lung function (Peak Expiratory Flow variability) despite treatment. Recognizing and managing this rare disease is crucial due to its high risk of life-threatening attacks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First Search for B→X_{s}νν[over ¯] Decays.

Physical review letters·2026
Same author

Search for Feebly Interacting Particles in B Decays with Missing Energy at Belle.

Physical review letters·2026
Same author

Search for B^{0}→K^{*0}τ^{+}τ^{-} Decays at the Belle II Experiment.

Physical review letters·2025
Same author

Search for a Dark Higgs Boson Produced in Association with Inelastic Dark Matter at the Belle II Experiment.

Physical review letters·2025
Same author

Study of χ_{bJ}(2P)→ωϒ(1S) at Belle.

Physical review letters·2025
Same author

Search for Lepton-Flavor-Violating Decay Modes B^{0}→K_{S}^{0}τ^{±}ℓ^{∓} with Hadronic B Tagging at Belle and Belle II.

Physical review letters·2025
Same journal

Retraction Note: Can the endometrioma be an obstacle to complete oocyte retrieval in IVF cycles? A retrospective study.

European review for medical and pharmacological sciences·2026
Same journal

Retraction Note: A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients.

European review for medical and pharmacological sciences·2026
Same journal

Retraction Note: Oxycodone inhibits myocardial cell apoptosis after myocardial ischemia-reperfusion injury in rats via RhoA/ROCK1 signaling pathway.

European review for medical and pharmacological sciences·2026
Same journal

Intracoronary stem cell transplant in ischemic heart disease: a meta-analysis of randomized trials.

European review for medical and pharmacological sciences·2026
Same journal

From models to medicine: advanced preclinical systems and AI enabling RNA therapeutics in triple-negative breast cancer.

European review for medical and pharmacological sciences·2026
Same journal

Association of serum asprosin levels with obesity indices and metabolic parameters in adults.

European review for medical and pharmacological sciences·2026
See all related articles

Area of Science:

  • Pulmonology
  • Allergy and Immunology

Background:

  • Brittle asthma is a rare, severe asthma subtype defined by significant Peak Expiratory Flow (PEF) variability.
  • It is associated with life-threatening exacerbations and high morbidity, often requiring hospitalization.

Purpose of the Study:

  • To differentiate between Type 1 and Type 2 brittle asthma.
  • To highlight the diagnostic and therapeutic challenges posed by brittle asthma.

Main Methods:

  • Characterization of Type 1 brittle asthma: persistent PEF variability, female predominance (15-55 years), association with allergies and food intolerances.
  • Characterization of Type 2 brittle asthma: severe, acute attacks leading to respiratory failure or death.
  • Review of current therapeutic approaches including steroids and beta2-agonists.

Related Experiment Videos

Main Results:

  • Type 1 brittle asthma shows consistent PEF variability, often linked to allergies and personality disorders, necessitating close monitoring and treatment.
  • Type 2 brittle asthma presents with symptom-free intervals punctuated by severe, potentially fatal attacks requiring emergency care.
  • Both types pose significant clinical challenges due to their rarity and severity.

Conclusions:

  • Brittle asthma requires strict clinical recognition and management due to its high morbidity and mortality.
  • Understanding the distinct characteristics of Type 1 and Type 2 is essential for appropriate patient care.
  • Further research may improve diagnostic accuracy and treatment efficacy for this challenging condition.